All In Biotech

Drug Trial Radar · NCT05149326

KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

A Multicenter, Randomized, Double-Blind Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Gemcitabine and Nab-Paclitaxel Versus Placebo Combined With Gemcitabine and Nab-Paclitaxel in First Line Advanced Pancreatic Ductal Adenocarcinoma Subjects (ENREACH-PDAC-01).

Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

408

Planned (sponsor's estimate)

Start

Jan 20, 2022

Primary completion

Apr 30, 2024

Study completion Aug 30, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

Conditions

  • Advanced Pancreatic Ductal Adenocarcinoma

Interventions

  • KN046Drug

    KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.

  • placeboDrug

    placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: up to 2 years

Locations

65 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital Of Anhui medical University

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The Southwest Hospital of AMU

    Chongqing, Chongqing Municipality, China

  • The Third Affiliated Hospital of Army Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital,Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Affiliated Cancer Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Union Hospital Tongji Medical College Huazhong University of Science And Technology

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Nantong Tumor Hospital

    Nantong, Jiangsu, China

  • The Affiliated Hospital Of XuZhou Medical University

    Xuzhou, Jiangsu, China

  • First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.